Halozyme Therapeutics reported a robust first quarter for 2026, with total revenue reaching $377 million, a 42% increase year-over-year, driven by the growing adoption of ENHANZE-enabled products. Royalty revenues surged to $241 million, up 43%, primarily from key products like DARZALEX and VYVGART Hytrulo. The company also reaffirmed its full-year guidance, projecting ENHANZE royalties to exceed $1 billion for the first time, alongside an adjusted EBITDA margin expected to rise above 65%.
This impressive performance underscores the strength of Halozyme’s product portfolio and its effective capital allocation strategy, which includes a $1 billion share repurchase program aimed at enhancing shareholder value. The company plans to invest in organic growth, debt reduction, and potential future M&A opportunities within drug delivery technologies, although no non-drug delivery acquisitions are anticipated for 2026.
For market professionals, the key takeaway is Halozyme’s strong growth trajectory and commitment to returning capital to shareholders, positioning the company for sustained revenue growth and profitability as it continues to expand its ENHANZE pipeline and explore new collaborations.
Source: fool.com